Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17139471 | PROGRAMMABLE AND PORTABLE CRISPR-CAS TRANSCRIPTIONAL ACTIVATION IN BACTERIA | December 2020 | July 2023 | Allow | 30 | 1 | 1 | No | No |
| 17136080 | COMPOSITION AND METHOD FOR PREVENTING OR TREATING EYE DISORDER | December 2020 | April 2024 | Allow | 39 | 4 | 0 | No | No |
| 17122087 | ENGINEERED BI-STABLE TOGGLE SWITCH AND USES THEREOF | December 2020 | June 2023 | Abandon | 30 | 1 | 0 | No | No |
| 16973421 | NEXT GENERATION DESIGNER LIVER ORGANOIDS AND THEIR METHODS OF PREPARATION AND USE | December 2020 | December 2024 | Allow | 48 | 2 | 1 | Yes | No |
| 16972212 | METHODS FOR GENERATING HEMATOPOIETIC STEM CELLS | December 2020 | December 2024 | Allow | 48 | 2 | 1 | Yes | No |
| 17104231 | Gene Therapies, Systems, and Methods for Monitoring | November 2020 | March 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17104607 | METHODS AND COMPOSITIONS FOR INDUCING TUMOR CELL DEATH | November 2020 | April 2023 | Abandon | 29 | 1 | 0 | No | No |
| 16952267 | ARTIFICIAL SKELETAL MUSCLE TISSUE | November 2020 | January 2024 | Abandon | 38 | 2 | 1 | No | No |
| 16951220 | METHODS FOR ENGINEERING HUMAN PLURIPOTENT STEM CELLS FOR DIABETES THERAPY BY CO-TRANSDUCTION | November 2020 | April 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17093126 | METHODS OF IN VITRO DIFFERENTIATION OF MIDBRAIN DOPAMINE (MDA) NEURONS | November 2020 | May 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17091823 | HYPOXIA-INDUCIBLE FACTOR-2A AS A TARGET IN PREVENTION/TREATMENT OF PARKINSON'S DISEASE | November 2020 | February 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17050722 | CRYOPRESERVATION SOLUTION AND CRYOPRESERVATION METHOD | October 2020 | September 2024 | Abandon | 46 | 0 | 1 | No | No |
| 17071095 | VARIANTS OF CAS12A NUCLEASES AND METHODS OF MAKING AND USE THEREOF | October 2020 | October 2023 | Allow | 36 | 3 | 0 | Yes | No |
| 17046468 | SENSOR FUNCTIONALISED BIOINK | October 2020 | July 2024 | Abandon | 46 | 0 | 1 | No | No |
| 17045308 | DRUG SCREENING PLATFORM USING BIOMATERIAL SCAFFOLDS | October 2020 | March 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17043229 | DIFFERENTIATION MEDIUM AND METHOD FOR PREPARING OLIGODENDROCYTE PRECURSOR | September 2020 | July 2024 | Abandon | 46 | 2 | 1 | No | No |
| 17041677 | METHODS OF MODULATING ANTISENSE ACTIVITY | September 2020 | January 2025 | Abandon | 52 | 2 | 0 | No | No |
| 17028139 | MULTIPLEXABLE CRISPR EDITORS UTILIZING INTRACELLULAR EVOLVED APTAMERS FOR ENDOGENOUS EFFECTOR RECRUITMENT | September 2020 | March 2025 | Abandon | 54 | 4 | 1 | Yes | Yes |
| 17011292 | Humanized Knock-In Mouse Expressing Human Protein C. | September 2020 | October 2023 | Allow | 37 | 2 | 1 | No | No |
| 17001590 | HUMANIZED VIPR2 COPY NUMBER VARIANT TRANSGENIC MOUSE MODEL FOR ANTIPSYCHOTIC DRUG AND GENE THERAPY DISCOVERY FOR SCHIZOPHRENIA | August 2020 | April 2024 | Abandon | 43 | 3 | 0 | No | No |
| 16965835 | ACTIVATION-INDUCED TISSUE-EFFECTOR CELLS SUITABLE FOR CELL THERAPY AND EXTRACELLUAR VESICLES DERIVED THEREFROM | July 2020 | June 2025 | Abandon | 59 | 2 | 1 | No | No |
| 16833099 | METHOD OF TREATING OR PREVENTING HERNIA FORMATION | March 2020 | January 2024 | Allow | 46 | 5 | 0 | Yes | No |
| 16629485 | BIOSENSORS FOR MEASURING CELL SIGNALING IN STRESSED AND HEALTHY CELLS | January 2020 | February 2024 | Abandon | 49 | 1 | 1 | No | No |
| 16626227 | TRANSGENIC ANIMALS AND TRANSGENIC EMBRYOS PRODUCING AN ENGINEERED NUCLEASE | December 2019 | April 2024 | Allow | 52 | 3 | 0 | Yes | No |
| 16622739 | Genome Editing System For Repeat Expansion Mutation | December 2019 | May 2024 | Abandon | 53 | 4 | 0 | Yes | No |
| 16622509 | UNIVERSAL SELF-REGULATING MAMMALIAN CELL LINE PLATFORM FOR THE PRODUCTION OF BIOLOGICS | December 2019 | March 2024 | Allow | 51 | 2 | 1 | Yes | No |
| 16491208 | COMPOSITION CONTAINING C2CL ENDONUCLEASE FOR DIELECTRIC CALIBRATION AND METHOD FOR DIELECTRIC CALIBRATION USING SAME | December 2019 | April 2023 | Abandon | 43 | 2 | 0 | No | No |
| 16615854 | VIRAL EXPRESSION CONSTRUCT COMPRISING A FIBROBLAST GROWTH FACTOR 21 (FGF21) CODING SEQUENCE | November 2019 | December 2023 | Abandon | 49 | 2 | 1 | No | No |
| 16616216 | CELL CRYOPRESERVATION FORMULATION AND CELL RECOVERY METHOD | November 2019 | February 2025 | Abandon | 60 | 7 | 0 | No | No |
| 16687426 | HIGH ACTIVITY REGULATORY ELEMENTS | November 2019 | June 2024 | Allow | 55 | 3 | 1 | Yes | No |
| 16604785 | New Uses Of Mammalian Muscle-Derived Stem Cells | October 2019 | February 2024 | Abandon | 53 | 4 | 0 | Yes | No |
| 16484506 | FLUIDIC CHIP FOR CELL CULTURE USE, CULTURE VESSEL, AND CULTURE METHOD | August 2019 | October 2023 | Allow | 50 | 2 | 1 | Yes | No |
| 16527152 | EARLY-ONSET PARKINSON'S DISEASE MODEL: (D331Y) PLA2G6 KNOCKIN MODEL, PLATFORM AND METHOD FOR DRUG SCREENING, AND KIT OF DETECTION | July 2019 | June 2024 | Abandon | 58 | 3 | 1 | No | No |
| 16503481 | Preparation and application of immortalized alpha-1,3-galactosyltransferase gene knockout pig hepatocyte cell line | July 2019 | May 2023 | Abandon | 47 | 1 | 1 | No | No |
| 15960048 | PROMOTERS, EXPRESSION CASSETTES, VECTORS, KITS, AND METHODS FOR THE TREATMENT OF ACHROMATOPSIA AND OTHER DISEASES | April 2018 | May 2024 | Abandon | 60 | 6 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DHAR, MATASHA.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DHAR, MATASHA works in Art Unit 1632 and has examined 35 patent applications in our dataset. With an allowance rate of 34.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner DHAR, MATASHA's allowance rate of 34.3% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by DHAR, MATASHA receive 2.31 office actions before reaching final disposition. This places the examiner in the 61% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by DHAR, MATASHA is 46 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +62.0% benefit to allowance rate for applications examined by DHAR, MATASHA. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 19.4% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 15.4% of cases where such amendments are filed. This entry rate is in the 18% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
When applicants file petitions regarding this examiner's actions, 75.0% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.